Atrial Fibrillation and Coronary Artery Disease: Focus on Epidemiology and Pathophysiology in the Context of Comorbidity

Atrial fibrillation and coronary artery disease (CAD) are a common and clinically significant comorbidity. Based on various epidemiological studies, it is believed that the relationship between atrial fibrillation and CAD is complex and much closer than a mere coincidence. These two diseases share common risk factors that influence the underlying mechanisms of their development, contributing to a vicious cycle of their onset and progression. In this case, CAD can be both a cause and a consequence of atrial fibrillation.

The aim of this systematic review was to evaluate and compare the opinions of authors of various publications on the interactions between atrial fibrillation and CAD, taking into account the epidemiology and pathophysiological interactions between them.

Materials and methods. The PRISMA (Preferred Reporting Items for Systematic Reviews and MetaAnalyses) 2020 methodology was used to select relevant publications. According to these guidelines, 597 articles on the stated topic were identified in the PubMed and eLibrary.ru search engines. At the final stage, 74 English-language publications and 16 Russian-language publications were included in the review. Existing opinions in various publications often complement one other, although they are sometimes contradictory, requiring further in-depth research in this area. The pathophysiological findings suggest that these two diseases can form a vicious cycle, exacerbating each other. Understanding these interrelated mechanisms allows for a transition from symptomatic treatment to a pathogeneticallyfocused strategy aimed at breaking the vicious cycles linking atrial fibrillation and CAD.

1. Lippi G., Sanchis-Gomar F., Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int. J. Strok. 2021;16(2):217–221. DOI: 10.1177/1747493019897870.

2. Schnabel R.B., Yin X., Gona P., Larson M.G., Beiser A.S, McManus D.D. et al. 50year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386:154–162. DOI: 10.1016/S0140-6736(14)61774-8.

3. Oancea A.F., Jigoranu R.A., Morariu P.C., Miftode R.S., Trandabat B.A., Iov D.E. et al. Atrial fibrillation and chronic coronary ischemia: a challenging vicious circle. Life. 2023;13:1370. DOI: 10.3390/life13061370.

4. Rani S., Kumar L., Ali S.M.E., Ashraf S., Bhimani S., Kumar S. et al. Trends in United States mortality among patients with atrial fibrillation/flutter related heart failure (1999-2024): disparities by gender, race/ethnicity and region. BMC Cardiovasc. Disord. 2025;25(1):558. DOI: 10.1186/s12872-025-05036-5.

5. Nakamura M., Inoue H., Yamashita T., Akao M., Atarashi H Ikeda T. et al. Coronary events in elderly patients with non-valvular atrial fibrillation: a prespecified sub-analysis of the ANAFIE registry. Cardiovasc. Interv. Ther. 2024;39(2):145–155. DOI: 10.1007/s12928-024-00984-9.

6. Болдуева С.А., Соловьева М.В., Облавацкий Д.В., Феоктистова В.С. Инфаркт миокарда у больных с фибрилляцией предсердий. Кардиология. 2020;60(1):53–61. DOI: 10.18087/cardio.2020.1.n620.

7. Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. DOI: 10.136/bmj.n71.

8. Liang F., Wang Y. Coronary heart disease and atrial fibrillation: a vicious cycle. Am. J. Physiol. Heart Circ Physiol. 2021;320(1):H1–H12. DOI: 10.1152/ajpheart.00702.2020.

9. Li X., Zhang Y., Wang Y., Liu J., Liu Y., Zheng D. et al. Risk factors for coronary artery disease in patients with atrial fibrillation: A systematic review and meta-analysis of 35 prospective cohort studies. Int. J. Cardiol. 2023;387:131–142. DOI: 10.1016/j.ijcard.2023.05.038.

10. Van Gelder I.C., Rienstra M., Bunting K.V., Casado-Arroyo R., Caso V., Crijns H.J.G.M. et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio – Thoracic Surgery (EACTS). Eur. Heart J. 2024;45:3314–3414. DOI: 10.1093/eurheartj/ehaf306.

11. Kakkar A.K., Mueller K., Bassand J.P., Fitzmaurice D.A., Goldhaber S.Z., Goto S. et al. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart Journal. 2023;75(1):1–9. DOI: 10.1016/j.ihj.2023.01.008.

12. Bassand J.P., Apenteng P.N., Atar D., Camm A.J., Cools F., Corbalan R. et al. GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. Future Cardiol. 2021;17(1):19–38. DOI: 10.2217/fca-2020-0014.

13. Шляхто Е.В., Виллевальде С.В., Ежов А.В., Зенин С.А., Козиолова Н.А., Кореннова О.Ю. и др. Клинический портрет пациента с фибрилляцией предсердий в Российской Федерации. Данные глобального регистра GLORIA AF. Российский кардиологический журнал. 2017;9(149):21–27. DOI: 10.15829/1560-4071-20179-138-142.

14. Ding W.Y., Fawzy A.M., Romiti G.F., Proietti M., Pastori D., Huisman M.V. et al. GLORIA-AF Investigators. Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry. J. Thromb. Thrombolysis. 2024;57(1):39–49. DOI: 10.1007/s11239-023-02866-y.

15. Borschel C.S., Schnabel R.B. The imminent epidemic of atrial fibrillation and its concomitant diseases – myocardial infarction and heart failure – a cause for concern. Int. J. Cardiol. 2019;287: 62–73. DOI: 10.1016/j.ijcard.2018.11.123.

16. Кузин С.В., Ложкина Н.Г., Шефер Е.И., Рузанкин П.С. Прогнозирование фибрилляции предсердий у больных ишемической болезнью сердца с использованием методов математического моделирования. Российский кардиологический журнал. 2025;30(5):58–68. DOI: 10.15829/15604071-2025-5868.

17. Barnes G.D. Combining antiplatelet and anticoagulant therapy in cardiovascular disease. Hematology Am. Soc. Hematol. Educ. Program. 2020;2020:642–648. DOI: 10.1182/hematology.2020000151.

18. Польшакова И.Л., Поветкин С.В. Сравнительный анализ факторов, влияющих на прогноз у больных с фибрилляцией предсердий по результатам исследования РЕКУР-ФП. Рациональная фармакотерапия в кардиологии. 2019;15(5):649–655. DOI: 10.20996/1819-6446-2019-15-5-649-655.

19. Jani B.D., Nicholl B.I., McQueenie R., Connelly D.T., Hanlon P., Gallacher K.I. et al. Multimorbidity and co-morbidity in atrial fibrillation and effects on survival: findings from UK Biobank cohort. Europace. 2018 20(FI_3):f329–f336. DOI: 10.1093/europace/eux322.

20. Хорькова Н.Ю., Харац В.Е., Гизатулина Т.П., Хрущева О.А. Фибрилляция предсердий в реальной клинической практике: дефекты интерпретации электрокардиограммы. Сибирский медицинский журнал. 2019;34(2):99–105. DOI: 10.29001/2073-8552-2019-34-2-99-105.

21. Пелиновская Л.И., Демко И.В., Мандрикова О.М., Глизер Р.Н. Частота и характер поражения коронарных артерий у больных с фибрилляцией предсердий. Сибирское медицинское обозрение. 2013;4:60–62.

22. Лукьянов М.М., Марцевич С.Ю., Андреенко Е.Ю., Якушин С.С., Воробьев А.Н., Переверзева К.Г. и др. Сочетание фибрилляции предсердий и ишемической болезни сердца у пациентов в клинической практике: сопутствующие заболевания, фармакотерапия и исходы (данные регистров РЕКВАЗА). Рациональная фармакотерапия в кардиологии. 2021;17(5):702–711. DOI: 10.20996/1819-6446-2021-10-03.

23. Шевченко Н.М., Богданова Е.Я., Шуаева Р.Г., Рыжова Т.В. Мерцательная аритмия. Ж. «Доктор Ру». 2004;24–29.

24. Lévy S., Maarek M., Coumel P., Guize L., Lekieffre J., Medvedowsky J.L. et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation. 1999;99(23):3028–3035. DOI: 10.1161/01.cir.99.23.3028.

25. Ярославская Е.И., Кузнецов В.А., Горбатенко Е.А., Марьинских Л.В. Связь фибрилляции предсердий с поражением коронарного русла у больных ишемической болезнью сердца. Кардиология. 2019;59(9):5–12. DOI: 10.18087/cardio.2019.9.2641.

26. Michniewicz E., Mlodawska E., Lopatowska P., Tomaszuk-Kazberuk A., Malyszko J. Patients with atrial fibrillation and coronary artery disease – Double trouble. Med. Sci. 2018;63(1):30–35. DOI: 10.1016/j.advms.2017.06.005.

27. Kralev S., Schneider K., Lang S., Süselbeck T., Borggrefe M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS One. 2011;6(9):e24964. DOI: 10.1371/journal.pone.0024964.

28. Packer D.L., Mark D.B., Robb R.A., Monahan K.H., Bahnson T.D., Poole J.E. et al. CABANA Investigators. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1261–1274. DOI: 10.1001/jama.2019.0693.

29. Kirchhof P., Camm A.J, Goette A., Brandes A., Eckardt L., Elvan A. et al. EAST-AFNET 4 Trial Investigators. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N. Engl. J. Med. 2020;383(14):1305–1316. DOI: 10.1056/NEJMoa2019422.

30. Ozierański K., Kapłon-Cieślicka A., Peller M., Tymińska A., Balsam P., Galas M. et al. Clinical characteristics and predictors of one-year outcome of heart failure patients with atrial fibrillation compared to heart failure patients in sinus rhythm. Kardiol. Pol. 2016;74(3):251–261. DOI: 10.5603/KP.a2015.0180.

31. Lopes R.D., Heizer G., Aronson R., Vora A.N., Massaro T., Mehran R. et al. AUGUSTUS Investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N. Engl. J. Med. 2019;380(16):1509–1524. DOI: 10.1056/NEJMoa1817083.

32. Vranckx P., Valgimigli M., Eckardt L., Tijssen J., Lewalter T., Gargiulo G. et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019; 394(10206):1335–1343. DOI: 10.1016/S0140-6736(19)31872-0.

33. Valgimigli M., Frigoli E., Heg D., Tijssen J., Jüni P., Vranckx P. et al. MASTER DAPT Investigators. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N. Engl. J. Med. 2021;385(18):1643–1655. DOI: 10.1056/NEJMoa2108749.

34. Willems S., Borof K., Brandes A., Breithardt G., Camm A.J., Crijns H.J.G.M. et al. Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. Eur. Heart J. 2022;43(12):1219– 1230. DOI: 10.1093/eurheartj/ehab593.

35. Люсов В.А., Агеев Ф.Т., Андреенко Е.Ю., Бойцов С.А., Виллевальде С.В., Галявич А.С. и др. Характеристика пациентов с фибрилляцией предсердий в реальной клинической практике: данные российского регистра РАФА-ФП. Кардиология. 2023;63(5):28–35. DOI: 10.18087/cardio.2023.5.n2418.

36. Бойцов С.А., Якушин С.С., Лукина Ю.В., Марцевич С.Ю., Кутихина М.Г., Либис Р.В. и др. Эпидемиология фибрилляции предсердий в Российской Федерации по данным регистра РОСФИ. Кардиология. 2023;63(3):15–23. DOI: 10.18087/cardio.2023.3.n2387.

37. Lewis W.R., Fonarow G.C., Grau-Sepulveda M.V., Smith E.E., Schwamm L.H., Xian Y. et al. Get with the guidelines – afib: quality of care and outcomes for patients with atrial fibrillation. JAMA Cardiology. 2023;8(5):483–492. DOI: 10.1001/jamacardio.2023.0104.

38. Hammoudeh A., Badaineh Y., Tabbalat R., Ahmad A., Bahhour M., Ja’ara D. et al. The Intersection of Atrial Fibrillation and Coronary Artery Disease in Middle Eastern Patients. Analysis from the Jordan Atrial Fibrillation Study. Global Heart. 2024;19(1):29. DOI: 10.5334/gh.1312.

39. Гуревич М.А., Либис Р.В., Орлова Я.А., Барбараш О.Л., Драпкина О.М., Лукина Ю.В. и др. Профиль антитромботической терапии и исходы у пациентов с фибрилляцией предсердий в реальной клинической практике: данные регистра ПРОФИЛЬ-ФП. Рациональная фармакотерапия в кардиологии. 2024;20(2):234–241. DOI: 10.20996/1819-6446-2024-20-2-234-241.

40. Mekhael M., Marrouche N., Hajjar A.H.E., Donnellan E. The relationship between atrial fibrillation and coronary artery disease: Understanding common denominators. Trends Cardiovasc. Med. 2024;34(2):91–98. DOI: 10.1016/j.tcm.2022.09.006.

41. Malavasi V.L., Proietti M., Spagni S., Tordoni M., Rotali F., Boriani G. Atherosclerotic Cardiovascular Disease and Ischemic Stroke in Atrial Fibrillation: A Systematic Review. Journal of Clinical Medicine. 2023;12(15):5003. DOI: 10.3390/jcm1255003.

42. Tsao C.W., Aday A.W., Almarzooq Z.I., Anderson C.A.M., Arora P., Avery C.L. et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023;147(8):e93–e621. DOI: 10.1161/CIR.0000000000001123.

43. Gallucci G., Russo V., DeRosa G., Silverio A. Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease: A Comprehensive Review. J. Clin. Med. 2023;12:681. DOI: 10.3390/jcm12020681.

44. Trohman R.G., Huang H.D., Sharma P.S. Atrial fibrillation: primary prevention, secondary prevention, and prevention of thromboembolic complications: part 1. Front. Cardiovasc. Med. 2023; 10:1060030. DOI: 10.3389/fcvm.2023.1060030.

45. Jang S.Y., Kang K.W., Kim J.H., Kim B., Chin J.Y., Park S.H. et al. New-onset atrial fibrillation predicting for complicating cardiac adverse outcome in scrub typhus infection. Clin. Cardiol. 2019;42(12):1210–1221. DOI: 10.1002/clc.23276.

46. Bechlioulis A., Rammos A., Papadopoulos A., Zotou P., Alexiou S., Kekiopoulou A. et al. Atrial fibrillation as an independent predictor of myocardial ischemia. Medicina (Kaunas). 2025;61(2):337. DOI: 10.3390/medicina61020337.

47. Ойноткинова О.Ш., Ройтберг Г.Е., Мацкеплишвили С.Т., Ларина В.Н., Гаврилова А.А., Масленникова O.M и др. Фибрилляция предсердий. Клинические рекомендации – 2024. Краткий обзор. Эффективная фармакотерапия. 2024;20(43):8–16. DOI: 10.33978/2307-3586-2024-20-43-8-16.

48. Люсов В.А, Силина Е.В., Марцевич С.Ю., Лукьянов М.М., Якушкин С.С., Деев А.Д. и др. Динамика назначения антикоагулянтной терапии пациентам с фибрилляцией предсердий в реальной клинической практике: данные исследования РЕКОРД-2. Рациональная фармакотерапия в кардиологии. 2022;18(3):269–277. DOI: 10.20996/1819-6446-2022-07-01.

49. Батурина О.А., Андреев Д.А., Ананичева Н.А., Гиляров М.Ю., Сычев Д.А., Сыркин А. Л.И. др. Распространенность фибрилляции предсердий при остром коронарном синдроме и особенности назначения пероральных антитромботических препаратов. Кардиология. 2019;59(1):40– 48. DOI: 10.18087/cardio.2019.1.10213.

50. Зыков М.В., Барбараш О.Л. Патогенетические и клинические аспекты фибрилляции предсердий при инфаркте миокарда. Российский кардиологический журнал. 2021;26(2):4307. DOI: 10.15829/1560-4071-2021 43072-7.

51. Buchta P., Kalarus Z., Mizia-Stec K., Myrda K., Skrzypek M., Ga Sior M. De novo and pre-existing atrial fibrillation in acute coronary syndromes: impact on prognosis and cardiovascular events in long-term follow-up. Eur. Heart J. Acute Cardiovasc. Care. 2021;10(10):1129–1139. DOI: 10.1093/ehjacc/zuab091.

52. Braga C.G., Ramos V., Martins J., Arantes C., Abreu G., Vieira C. et al. Impact of atrial fibrillation type during acute coronary syndromes: Clinical features and prognosis. Rev. Port. Cardiol. 2015;34(6):403–410. DOI: 10.1016/j.repc.2015.01.010.

53. Lopes R.D., Pieper K.S., Horton J.R., Al-Khatib S.M., Newby L.K., Mehta R.H. et al. Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart. 2008; 4(7):867–873. DOI: 10.1136/hrt.2007.134486.

54. Takafuji M., Kitagawa K., Nakamura S., Kokawa T., Kagawa Y., Fujita S. et al. Hyperemic myocardial blood flow in patients with atrial fibrillation before and after catheter ablation: A dynamic stress CT perfusion study. Physiol. Rep. 2021;9(22):e15123. DOI: 10.14814/phy2.15123.

55. Shiba T., Kondo Y., Senoo K., Nakano M., Okubo K., Ishio N. et al. Proximal occlusion in the right coronary artery involving the atrial branch as a strong predictor of new-onset atrial fibrillation in acute myocardial infarction. Int. Heart J. 2019;60:1308–1314. DOI: 10.1536/ihj.18-713.

56. Shakeel I., Sharma H., Hodson J., Iqbal H., Tashfeen R., Ludman P.F. et al. Prevalence and impact of сoncomitant atrial fibrillation in patients undergoing percutaneous coronaryiIntervention for acute myocardial infarction. J. Clin. Med. 2024;13(8):2318. DOI: 10.3390/jcm13082318.

57. Baig M.F.A. NSTEMI mortality and hospital outcomes in patients with atrial fibrillation: A propensity score-matched analysis. Int. J. Cardiol. Heart Vasc. 2024;52:101402. DOI: 10.1016/j.ijcha.2024.101402.

58. Shiyovich A., Axelrod M., Gilutz H. Early Versus late new-onset atrial fibrillation in acute myocardial infarction: differences in clinical characteristics and predictors. Plakht. Angiology. 2019;70(10):921–928. DOI: 10.1177/0003319719867542.

59. Van Diepen S., Siha H., Fu Y., Westerhout C.M., Lopes R.D., Granger C.B. et al. APEXAMI Investigators. Do baseline atrial electrocardiographic and infarction patterns predict new-onset atrial fibrillation after ST-elevation myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. J. Electrocardiol. 2010;43:351–358. DOI: 10.1016/j.jelectrocard.2010.04.001.

60. Pokorney S.D., Berchuck S.I., Chiswell K., Sun J.L., Thomas L., Jones W.S. et al. Atrial branch coronary artery stenosis as a mechanism for atrial fibrillation. Heart Rhythm. 2022; 19(8):1237–1244. DOI: 10.1016/j.hrthm.2021.12.020.

61. Khadair D., Alshengieti L., Elbarouni B., Goodman S.G., Yan A.T. Global Registry of Acute Coronary Events (GRACE/GRACE2) and the Canadian Registry of Coronary Events (CANRACE) Investigators. Management and outcome of acute coronary syndrome patients in relation to prior history of atrial fibrillation. Can. J. Cardiol. 2012;28(4):443–449. DOI: 10.1016/j.cjca.2011.12.011.

62. Andreini D., Maggioni A.P., Pontone G., Mushtag S., Bertella E., Segurini C. et al. CT Coronary Angiography in Patients With Atrial Fibrillation: Results From the AFIB-CT Study. JACC: Cardiovasc. Imag. 2023;16(4):489–501. DOI: 10.1016/j.jcmg.2022.11.012.

63. Zimmermann F.M, Omerovic E., Fournier S., Kelbak H., Johnson N.P., Rothenbuhler M. et al. Fractional Flow Reserve- Guided PCI in Patients With Atrial Fibrillation: A Substudy of the FAME 3 Trial. Circ. Cardiovasc. Interv. 2023;16(4):e012345. DOI: 10.1161/CIRCINTERVENTIONS.122.012345.

64. Tomaszuk-Kazberuk A., Koziński M., Kuźma Ł., Bujno E., Łopatowska P., Rogalska E. et al. Atrial fibrillation is more frequently associated with nonobstructive coronary lesions: the Bialystok Coronary Project. Pol. Arch. Intern. Med. 2020;130(12):1029–1036. DOI: 10.20452/pamw.15635.

65. Pintea Bentea G., Berdaoui B., Morissens M., van de Borne P., Castro Rodriguez J. Pathophysiology, diagnosis, and management of coronary artery disease in the setting of atrial fibrillation. J. Am. Heart Assoc. 2024;13(23):e037552. DOI: 10.1161/JAHA.124.037552.

66. Batta A., Hatwal J., Batta A., Verma S., Sharma Y.P. Atrial fibrillation and coronary artery disease: an integrative review focusing on therapeutic implications of this relationship. World J. Cardiol. 2023;15:229–243. DOI: 10.4330/wjc.v15.i5.229.

67. Corban M.T., Godo S., Burczak D.R., Noseworthy P.A., Toya T., Lewis B.R. et al. Coronary endothelial dysfunction is associated with increased risk of incident atrial fibrillation. J. Am. Heart Assoc. 2020;9(8):e014850. DOI: 10.1161/JAHA.119.014850.

68. Sikora W., Kanikowska D., Budzianowski J., Kawka E., Rutkowski R., Korybalska K. Assessment of Blood Endothelial Cell Biomarkers in Women and Men with Abnormal Body Mass and Paroxysmal Atrial Fibrillation Based on CHA2DS2-VASC Score: A Retrospective Study. Int. J. Mol. Sci. 2025;26(8):3627. DOI: 10.3390/ijms26083627.

69. Libby P., Emingil G., Luscher T.F., Hansson G.K., Shimokawa H., Back M. et al. Inflammation and its resolutiom in atherosclerosis: mediators and therapeutic opportunities. Nat. Rev. Cardiol. 2024;21(2):105–118. DOI: 10.1038/s41569-023-00915-w.

70. Zakynthinos G.E., Tsolaki V., Oikonomou E., Pantelidis P., Gialamas I., Kalogeras K. et al. Unveiling the role of endothelial dysfunction: a possible key to enhancing catheter ablation success in atrial fibrillation. Int. J. Mol. Sci. 2024;25:2317. DOI: 10.3390/ijms25042317.

71. Souilhol C., Evans C.E., Luisaint N., Lepland A., Ward S., Khan S. et al. Circulating endothelial cells as a novel biomarker for coronary artery disease detection in patients with atrial fibrillation. Eur. Heart J. 2024;45(24):2156–2168. DOI: 101093/eurheartj/ehae287.

72. Mehta V., Pang K.L., Rozbesky D., Nather K., Keen A., Lachowski D. et al. The guidance receptor plexin D1 is a mechanosensor in endothelial cells. Nature. 2020;578:290–295. DOI: 10.1038/s41586-020-1979-4.

73. Hara T., Phuong P.T., Fukuda D., Yamaguchi K., Murata C., Nishimoto S. et al. Protease-activated receptor-2 plays a critical role in vascular inflammation and atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2018;138:1706– 1719. DOI: 10.1161/CIRCULATIONAHA.118.033544.

74. Pan J., Xu C., Xu B., Lou Y., Wang S., Xing Y. Relationship between the time point of left atrial size change Pan and the outcomes of radiofrequency catheter ablation. J. Interv. Card. Electrophysiol. 2022;64(3):669–675. DOI: 10.1007/s10840-021-01097-6.

75. Dungan G.D., Kantarcioglu B., Odeh A., Hoppensteadt D., Siddiqui F., Rohde L. et al. Vascular endothelial dysfunction and immunothrombosis in the pathogenesis of atrial fibrillation. Clin. Appl. Thromb. Hemost. 2024;30:10760296241296138. DOI: 10.1177/10760296241296138.

76. Lau D.H., Nattel S., Kalman J.M., Sanders P. Modifiable risk factors and atrial fibrillation. Circulation. 2017;136:583–596. DOI: 10.1161/CIRCULATIONAHA.116.023163.

77. Staerk L., Sherer J.A., Ko D., Benjamin E.J., Helm R.H. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ. Res. 2017;120(9):1501–1517. DOI: 10.1161/CIRCRESAHA.117.309732.

78. Cheniti G., Vlachos K., Pambrun T., Hooks D., Frontera A., Takigawa M. et al. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ. Res. 2014;114:1483–1499. DOI: 10.1161/CIRCRESAHA.114.302226.

79. Shu C., Huang W., Zeng Z., He Y, Luo B., Liu H. et al. Connexin 43 is involved in the sympathetic atrial fibrillation in canine and canine atrial myocytes. Anatol. J. Cardiol. 2017;18(1):3–9. DOI: 10.14744/AnatolJCardiol.2017.7602.

80. Chen P.S., Chen L.S., Fishbein M.C., Lin S.F., Nattel S. Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. Circ. Res. 2014;114:1500–1515. DOI: 10.1161/CIRCRESAHA.114.303772.

81. Zukela T., Zhou Q., Wang H., Zhou X., Li Y., Zhang Y. et al. Relationship between new-onset atrial fibrillation and sympathetic neural remodeling in a canine acute myocardial infarction model. Zhonghua Xin Xue Guan Bing Za Zhi. 2015;43:975–981.

82. Bahouth F., Mutlak D., Furman M., Musallam A., Hammerman H., Lessick J. et al. Relationship of functional mitral regurgitation to new-onset atrial fibrillation in acute myocardial infarction. Heart. 2010;96(9):683–688. DOI: 10.1136/hrt.2009.183822.

83. Aronson D., Mutlak D., Bahouth F., Bishara R., Hammerman H., Lessick J. et al. Restrictive left ventricular filling pattern and risk of new-onset atrial fibrillation after acute myocardial infarction. Am. J. Cardiol. 2011;107(12):1738–1743. DOI: 10.1016/j.amjcard.2011.02.334.

84. Xintarakou A., Tzeis S., Psarras S., Asvestas D., Vardas P. Atrial fibrosis as a dominant factor for the development of atrial fibrillation: facts and gaps. Europace. 2020;22(3):342–351. DOI: 10.1093/europace/euaa009.

85. Luckett L.R., Gallucci R.M. Interleukin-6 (IL-6) modulates migration and matrix metalloproteinase function in dermal fibroblasts from IL-6KO mice. Br. J. Dermatol. 2007;156(6):1163– 1171. DOI: 10.1111/j.1365-2133.2007.07867.x.

86. Tsai W.C., Hung T.C., Kusayama T., Han S., Fishbein M.C., Chen L.S., Chen P.S. Autonomic modulation of atrial fibrillation. JACC Basic Transl. Sci. 2023;8(10):1398–1410. DOI: 10.1016/j.jacbts.2023.03.019.

87. Zhang P., Shao L., Ma J. Toll‐like receptors 2 and 4 predict new‐onset atrial fibrillation in acute myocardial infarction patients. Int. Heart J. 2018;59:64–70. DOI: 10.1536/ihj.17-084.

88. Nishida K., Qi X.Y., Wakili R., Comtois P., Chartier D., Harada M. et al. Mechanisms of atrial tachyarrhythmias associated with coronary artery occlusion in a chronic canine model. Circulation. 2011;123(2):137–146. DOI: 10.1161/CIRCULATIONAHA.110.972778.

89. Kochiadakis G.E., Kallergis E.M. Impact of Atrial Fibrillation on Coronary Blood Flow: A Systematic Review. J. Atr. Fibrillation. 2012;5(3):458. DOI: 10.4022/jafib.458.

90. Lin J., Lin H., Xu Z., Yang Z., Hong C., Wang Y. et al. Angiogenesis in Atrial Fibrillation: A Literature Review. Biomedicines. 2025;13:1399. DOI: 10.3390/biomedicines13061399.